Study
|
Sample sizea(% men)
|
Age, yearsb
|
Diagnoses
|
Disease severityb
|
---|
SAPS III
|
SOFA
|
APACHE III
|
Other
|
---|
Abdellaoui et al.[42]
|
C: 6 (100%)
|
C: 67(59–72)
|
COPD
| | | |
C: FEV1 of 15(10–27)%
|
N: 9 (78%)
|
N: 59(57–69)
| | | | |
N: FEV1 of 25(17–41)%
|
Gerovasili et al.[25]
|
C: 13 (62%)
|
C: 56(19)
|
Sepsis
|
C: 61(14)
|
C: 8(3)
|
C: 18(6)
| |
N: 13 (46%)
|
N: 59(23)
|
Trauma
|
N: 66(9)
|
N: 10(3)
|
N: 19(3)
| |
| |
Neurologic
| | | | |
Gruther et al.[43]
|
C(A): 9 (89%)
|
C(A): 48(12)
|
Polytrauma
| | | | |
N(A): 8 (88%)
|
N(A): 52(10)
|
Cardiovascular
| | | | |
C(L): 8 (50%)
|
C(L): 64(8)
|
Transplant
| | | | |
N(L): 8 (88%)
|
N(L): 61(10)
|
Pneumonia
| | | | |
| |
Cancer
| | | | |
Karatzanos et al.[34] and Routsi et al.[35]
|
C: 28 (79%)
|
C: 59(21)
|
Sepsis
|
C: 58(14)
|
C: 8(3)
|
C: 19(5)
|
C: 39% with CIPNM
|
N: 24 (79%)
|
N: 55(20)
|
Trauma
|
N: 55(11)
|
N: 8(3)
|
N: 16(4)
|
N: 13% with CIPNM
|
| |
Post-surgery
| | | | |
| |
Brain injury
| | | | |
| |
Respiratory failure
| | | | |
Poulsen et al.[44]
|
C/N: 8 (100%)
|
C/N: 67(64–72)
|
Sepsis
| |
C/N: 11(9–14)
|
C/N: 25(20–29)
|
C/N: 13(10–22) days in ICU
|
Rodríguez et al.[45]c
|
C/N: 14 (50%)
|
C/N: 72(63–80)
|
Sepsis
| |
C/N: 10(9–12)
|
C/N: 20(18–27)
|
C/N: 27(19–44) days in ICU
|
Zanotti et al.[46]
|
C: 12 (67%)
|
C: 65(4)
|
COPD
| | | |
C: 47(19) days in ICU
|
N: 12 (75%)
|
N: 66(8)
| | | | |
N: 52(15) days in ICU
|
- A, acute; APACHE III, Acute Physiology and Chronic Health Evaluation III; C, control group; CIPNM, critical illness polyneuromyopathy; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; ICU, intensive care unit; L, long-term; N, neuromuscular electrical stimulation group; SAPS III, Simplified Acute Physiology Score III; SOFA, Sequential Organ Failure Assessment.
-
aOnly patients included in the analysis of the outcomes of interest are shown.
-
bData are provided as means (standard deviation) or medians (interquartile range).
-
cThe contralateral side acted as control.